Apr 30, 2025 · 27m · a16z
Biotech CEO on where we are in the fight to cure cancer
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of the a16z podcast Raising Health, host Jorge Conde interviews physician-turned-entrepreneur Dr. Jonathan Lim about his leadership in biotechnology, novel cancer therapies targeting the RAS pathway, and the surprising parallels between drug development and film production.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
speaking balance: gold is the host, purple is the guest (3 minute bins)
The guest openly challenges the initial premise that wild-type RAS could be targeted, noting he was extremely skeptical until forced to yield to convincing data.
Hardest push from the host ▶ 7:43 Host challenges genetic premise with straw-man argumentThe host sets up a deliberate counter-framing, questioning whether sequencing alone should theoretically allow us to work backwards and defeat all cancers.
Biggest teaching moment ▶ 8:24 Guest reveals unknown ecDNA mechanismsThe guest educates the host on circular extra-chromosomal DNA, explaining a key mechanism of oncogene amplification that most of the industry was previously unaware of.
The host holds their own ▶ 24:37 Host connects hit-driven dynamic across industriesThe host demonstrates sharp industry intuition by directly connecting upfront capital risks, development hell, and reliance on hits between film and biotech.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| From Surgeon to Biotech CEO: The Halozyme Story | 2 | 3 | 1 | 2 | The host guides the interview through the guest's career shift from surgeon to McKinsey consultant and early startup CEO. The tone is casual and conversational, with the guest humbly explaining his early lack of biotech knowledge. | |
| City Hill Ventures and Entrepreneurial Biotechs | 3 | 4 | 1 | 1 | The guest outlines current progress in cancer treatments, highlighting checkpoint inhibitors, long tail survival curves, and antibody-drug conjugates like Enhertu. The host prompts with open-ended framing while the guest delivers technical context. | |
| Deciphering Cancer Genetics and ecDNA | 4 | 6 | 3 | 3 | The host presents a simplified straw-man hypothesis about genetic sequencing solving cancer. The guest reframes this by educating the host on extra-chromosomal DNA (ecDNA) and circular chromosomal structures driving resistance. | |
| Next-Generation Modalities for Undruggable Targets | 3 | 5 | 2 | 1 | The guest explains novel molecular glues and cyclophilin A binders targeting GTP active state RAS, admitting his prior personal skepticism before seeing data. The discussion transitions into an anecdotal story about Galapagos wildlife adaptation. | |
| Pivoting Pipelines and Strategic Capital Discipline | 4 | 5 | 1 | 1 | The guest shares startup strategy and capital discipline, describing how Araska pivoted pipelines and preserved cash following its public offering. The host asks targeted questions about founder adaptations during market shifts. | |
| Venturing into Hollywood: Founding City Hill Arts | 3 | 4 | 0 | 1 | The host playfully explores the guest's venture into Hollywood film production with City Hill Arts. The guest outlines the production details and puppet-to-CGI breakdown for his penguin feature film. | |
| Parallels Between Biotech and Film Production | 5 | 5 | 2 | 1 | The host proactively identifies structural parallels between biotech drug development and movie production around hit dependence and development hell. The guest confirms the comparison with industry timelines and statistics. |